Jena University Hospital, School of Medicine, Department of Virology and Antiviral Therapy, Hans-Knöll-Str. 2, 07745 Jena, Germany; Department of Clinical Pharmacy and Pharmacotherapy, Institute of Pharmacy, Martin-Luther-University Halle-Wittenberg, Wolfgang-Langenbeck-Str. 4, D-06120 Halle (Saale), Germany.
Centre for Molecular Informatics, Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, United Kingdom; University of Hamburg, Center for Bioinformatics, Bundesstraße 43, 20146 Hamburg, Germany.
Antiviral Res. 2015 Nov;123:138-45. doi: 10.1016/j.antiviral.2015.09.009. Epub 2015 Sep 25.
Enteroviruses cause various acute and chronic diseases. The most promising therapeutics for these infections are capsid-binding molecules. These can act against a broad spectrum of enteroviruses, but emerging resistant virus variants threaten their efficacy. All known enterovirus variants with high-level resistance toward capsid-binding molecules have mutations of residues directly involved in the formation of the hydrophobic binding site. This is a first report of substitutions outside the binding pocket causing this type of drug resistance: I1207K and I1207R of the viral capsid protein 1 of coxsackievirus B3. Both substitutions completely abolish the antiviral activity of pleconaril (a capsid-binding molecule) but do not affect viral replication rates in vitro. Molecular dynamics simulations indicate that the resistance mechanism is mediated by a conformational rearrangement of R1095, which is a neighboring residue of 1207 located at the heel of the binding pocket. These insights provide a basis for the design of resistance-breaking inhibitors.
肠道病毒可引起多种急性和慢性疾病。针对这些感染,最有前途的治疗方法是衣壳结合分子。这些分子可以对抗广泛的肠道病毒,但新兴的耐药病毒变异体威胁着它们的疗效。所有已知对衣壳结合分子具有高水平耐药性的肠道病毒变异体都具有直接参与形成疏水性结合位点的残基突变。这是首次报道结合口袋外的取代导致这种类型的耐药性:柯萨奇病毒 B3 的病毒衣壳蛋白 1 中的 I1207K 和 I1207R。这两种取代完全消除了普乐可复(一种衣壳结合分子)的抗病毒活性,但不影响病毒在体外的复制率。分子动力学模拟表明,耐药机制是由位于结合口袋后跟的 1207 附近残基 R1095 的构象重排介导的。这些见解为设计耐药性突破抑制剂提供了依据。